Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film

Table 2 Effect of topical dorzolamide, benzalkonium-preserved dorzolamide, and benzalkonium-preserved brinzolamide on the Total Oxidant Status (TOS), Total Antioxidant Reactivity (TAR) and Oxidative Stress Index (OSI) in the tear film

Parameter/group	C	DL	DL+BAC	BL+BAC
TOS [nmol H₂O₂/ml]	0.069 ± 0.003	0.074 ± 0.004	0.083 ± 0.002*	0.085 ± 0.004**
TAR [nmol trolox/ml]	0.066 ± 0.003	0.075 ± 0.005	0.068 ± 0.002	0.070 ± 0.002
OSI	1.05 ± 0.02	1.03 ± 0.07	1.23 ± 0.05**^^	1.22 ± 0.05**^^

C - control group (n = 25); DL - patients with glaucoma using topical dorzolamide (n = 14); DL+BAC - patients with glaucoma using topical dorzolamide + benzalkonium chloride (BAC) (n = 16); BL+BAC - patients with glaucoma using topical brinzolamide + BAC (n = 17)
Results are presented as means ± SEM. * p < 0.05, ** p < 0.01—statistically significantly different from the C group. ^^ p < 0.01—statistically significantly different from the DL group

ISSN: 1471-2415